RxDoctor Payments Data

Mark Christ, MD

Urology · Aventura, FLNPI 1144284688

Payments from drug & device makers

$7,657in general payments, 2019–2025

Across 278 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calyxo, Inc.$1K
  • Johnson & Johnson$1K
  • Myriad Genetic Laboratories, Inc.$879
  • Boston Scientific$538
  • Axonics, Inc.$447
  • Endo Pharmaceuticals Inc.$420
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$96313%
  • Food & beverage$6,40684%
  • Education$2884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,657 in reported general payments places this provider in the 65th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$87,890
Medicare patients
250
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate154$924,036
ErleadaApalutamide26$392,216
TrelstarTriptorelin Pamoate48$121,032
MyrbetriqMirabegron82$79,137
GemtesaVibegron85$77,498
EligardLeuprolide Acetate32$42,737
Tamsulosin Hcl598$9,219
Methenamine Hippurate79$4,034
Bicalutamide51$2,733
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst151$2,510
Finasteride180$2,422
Potassium Citrate ErPotassium Citrate14$2,054
Oxybutynin Chloride ErOxybutynin Chloride56$1,450
Ciprofloxacin Hcl103$1,137
Tadalafil35$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$286$924,036154 claims
Johnson & JohnsonErleada$1,104$392,21626 claims
Verity Pharmaceuticals Inc.Trelstar$121$121,03248 claims
Astellas Pharma US IncMyrbetriq$219$79,13782 claims
Sumitomo Pharma America, Inc.Gemtesa$197$77,49885 claims
Tolmar Pharmaceuticals, Inc.Eligard$109$42,73732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 urology providers in Florida.

Other urology in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →